In a report released today, Robert LeBoyer from Noble Financial reiterated a Buy rating on Ocugen (OCGN – Research Report), with a price target of $15.00. The company’s shares closed last Friday at $2.86.
According to TipRanks, LeBoyer is a 4-star analyst with an average return of 12.6% and a 35.66% success rate. LeBoyer covers the Healthcare sector, focusing on stocks such as Ayala Pharmaceuticals, Tonix Pharma, and PDS Biotechnology.
Currently, the analyst consensus on Ocugen is a Strong Buy with an average price target of $9.17.
See Insiders’ Hot Stocks on TipRanks >>
OCGN market cap is currently $616.8M and has a P/E ratio of (9.37).
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Ocugen, Inc. engages in the development and commercialization of therapies for eye diseases. Its pipeline of therapies includes OCU400, OCU410, OCU200, OCU100, and OCU300. The company was founded by Shankar Musunuri and Uday Kompella in 2013 and is headquartered in Malvern, PA.
Read More on OCGN:
- High Arctic to Announce 2022 Second Quarter Results
- Noble Financial Reaffirms Their Buy Rating on Great Lakes Dredge & Dock (GLDD)
- CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2022 Financial Results
- Noble Financial Sticks to Their Buy Rating for E. W. Scripps Company Class A (SSP)
- TRACON Pharmaceuticals Announces Submission of IND Application for CTLA-4 Antibody YH001 for the Treatment of Front-line Sarcoma Patients in Combination with Envafolimab
